Background. Probiotics are increasingly used in neonatal intensive care and prove to reduce rates of necrotizing enterocolitis (NEC), sepsis and all-cause mortality by meta-analyses.
INTRODUCTION
e development of intestinal microbiota in newborn infants, and its potential in uence on the infants´ health has become an important issue. Moreover, intensive care in critically ill very preterm neonates potentially alters the intestinal microbiota and possibly enables the growth of pathogens. Hence, dysbiosis of the intestine, or imbalance of intestinal microbiota, increases the risk of diseases with in ammatory background such as late onset sepsis (LOS) and necrotizing enterocolitis (NEC) in neonates (1) . Furthermore, these associated clinical conditions include antibiotic associated diarrhea (AAD), multiple organ dysfunction syndrome (MODS), and ventilator associated pneumonia (VAP), all of them resulting in prolonged hospital stays, increases in the cost of intensive care, and greater risks of mortality (1, 2) . e risk of VAP generally increases as gestational age decreases (3) (4) (5) and has been reported to occur in up to 26% at a birth weight below 750 grams (6) . Comparably, the risk of late-onset sepsis (LOS) increases by decreasing gestational age and varies geographically from 0.61% to 14.2% among hospitalized preterm infants (7) . Rates of LOS up to 65% in infants with a birth weight below 500 grams have been reported (7) . Probiotics -as summarized in a recent systematic meta-analysis -showed signicant bene ts by lowering NEC rates and all-cause neonatal mortality (8) . Probiotics increase the intestinal mucosal barrier to prevent the translocation of bacteria, exclude competitively potential pathogens, produce bacteriocins that kill pathogens, increase the amount of immunoglobulins by mucosal response, modulate host immune reactions to microbial products, and ameliorate enteral nutrition and gut maturation (9, 10) . Early enteral trophic feeding as used in our neonatal intensive care unit (NICU) with human milk in all very low birth weight infants prevents atrophy of gastrointestinal mucosa, supports the establishment of healthy gut micro ora, reduces the use of parenteral nutrition by facilitating full enteral feeding, and improves gut mucosal immunity (11) (12) (13) . Aim of the study was to analyze the prophylactic use of the probiotic Lactobacil-lus casei rhamnosus (LCR) given as part of a multimodal anti-infective regimen in very preterm neonates in respect to complications and possible side e ects. is regimen has been documented recently in critically ill term infants (14) , and the study design used was a retrospective observational STROBE compliant singlecenter cohort study.
METHODS
All very preterm infants admitted to the NICU of the Division of Neonatology of the Medical University of Graz between January 1, 2005 and December 31, 2015 were retrospectively adherent to the STROBE statement evaluated for analysis. Inclusion criteria were as follows: admission within the rst 24 hours of life, stay at the NICU for at least 7 days, and gestational age of 23 (+0) to 32 (+6) weeks. Exclusion criteria were as follows: admission to the NICU beyond the rst day of life, stay at the NICU for less than 7 days, admission to and stay at the surgical department, or death before day 7. Further, neonates were excluded when data were missing or unavailable regarding outcome parameters. All very preterm infants received the probiotic Lactobacillus casei rhamnosus (LCR) -Antibiophilus© 0.75 g [contains ≥ 0.75 x 108 colony forming units -CFU] per day divided in 2 doses-throughout the stay at the NICU. e multimodal anti-infective treatment additionally included enteral gentamycin (Refobacin© 40 mg Amp. 15 mg/kg/day divided in 2 doses) and enteral nystatin (Mycostatin© 1mL= 100.000 IU/ kg per day divided in 4 doses). e standardized enteral feeding regimen was applied to all preterm infants at the NICU and remained unchanged through the study time period. Enteral feeding of breast milk (expressed breast milk or pooled human milk) was initiated at day 1. A volume of 1-2 up to 5 mL was initiated every 4 hours when infants were stable. Daily enteral feeding was increased by 2-5 mL per feed and did not exceed 10 mL per feed and day. Total uid intake was 90-100 mL/kg/d at day 1 with daily increases up to 160 (180) mL/kg/day at day 7 to 10. Enteral feeding was interrupted if there were signs of intolerance de ned as the presence of gastric residuals exceeding 25% of the volume o ered within the previous 8 hours, abdominal distension, or blood in the stool. Total or partial parenteral nutrition was routinely maintained until 120 -150 mL/kg/day by enteral feeds were reached. All neonates in the study received concomitant therapy including antibiotics as considered appropriate by the attending physician. Data were collected from the local electronic database openMedocs® for all infants regarding gender, gestational age (weeks), birth weight (grams), small for gestational age (birth weight below 10. Percentile), umbilical artery pH, length of stay (days), Apgar scores at 1, 5, 10 minutes, respectively, days on ventilator support (invasive mechanical plus continuous positive airway pressure -CPAP -ventilation), spontaneous birth, cesarean section, breast milk feeding, formula feeding, combined human milk and formula feeding, duration of antibiotic treatment (days), and main diagnosis for treatment at the NICU. Infectious events were always tested by blood culture for LCR. Outcome parameters were checked for throughout the medical records of the neonates using the electronic patient data monitoring system (PDMS, Sanitas, Austria) at the NICU and the electronic documentation system called openMedocs (LKH University Hospital Graz, Austria). e following complications were looked for: Late-onset -NEC (onset day 7 or later), MODS, VAP, and LOS (day 7 and later). NEC was de ned according to the modied Bell's criteria as stage IIa or more (15, 16) . Signs and symptoms included abdominal pain, bloody stools, ileus (subileus), and pneumatosis intestinalis. MODS was de ned as the presence of at least 2 of 6 de ned criteria for multiple organ dysfunction (17, 18) that was mainly adapted from Goldberg et al. (17) not using the scoring system published recently (18): • Cardiovascular dysfunction (any of the following): Despite isotonic intravenous bolus ≥40 mL/kg; systolic blood pressure <5% for age or need for vasoactive drugs; capillary re ll time >3 seconds; urine output <0.5 ml/kg/h • Respiratory dysfunction (any of the following): PaCO2 >65 torr or 20 mm Hg over baseline. Proven need for >50% FiO2 to maintain saturation ≥92% • Neurologic dysfunction (any of the following): Seizures, irritability, and lethargy, any di erent from baseline neurologic function • rombocytopenia: Platelets <80 000/µL or decline of 50% from highest value over past 3 days in neonates with baseline low platelets (< 150000/µL) • Renal dysfunction: Creatinine ≥2 times upper limit for age or 2-fold increase in baseline creatinine in neonates with baseline elevations in creatinine. • Hepatic dysfunction (any of the following): Total bilirubin not applicable to newborn. ALT (alanine transaminase) 2 times upper limit of normal for age or 2-fold increase in baseline abnormal ALT For the diagnosis of VAP, the patient was required to have received mechanical ventilation for at least 48 hours and to have developed new and persistent radiographic evidence of focal in ltrates lasting for a minimum of 48 hours a er the initiation of mechanical ventilation. In addition, these patients had to receive antibiotics for treatment of VAP for at least 7 days (2). LOS was de ned as a nosocomial bacterial infection not present or incubating at the time of NICU admission and occurring at day 7 or later. We did not di erentiate between culture proven and clinical sepsis (clinical symptoms + 2 or more abnormal values including white blood cell count, neutrophils, immature to total neutrophil ratio >0.2 and C-reactive protein >8mg/L) (19 
RESULTS
Between January 1, 2005 and December 31, 2015, a total of 1287 very preterm infants were born. One hundred eighteen infants had to be excluded ( gure 1), thus, the study population comprised 1169 infants with a gestational age of 23+0 to 32+6 weeks. Perinatal data are given in table 1. Mean length of stay was 53 days (range 7 to 431). Respiratory support was given in 970 infants (83%). Mean duration of respiratory support was 19.5 days (range 1 -264). Di-agnosis of respiratory distress syndrome (RDS) was given in 813 infants (70%), 613 infants (52%) needed surfactant therapy.
irty-three infants (2.8%) had diagnosis of pneumothorax, 30 had wet lung (2.6%), 16 atelectasis (1.4%), 14 lung hypoplasia (1.2%), and 10 (0.9%) emphysema. Twenty-one had diagnosis of asphyxia (1.8%), and 16 (1.4%) had diagnosis of ileus. Four hundred and four (35%) infants were fed human milk, 225 (19%) were fed formula and 540 (46%) were fed both. Antibiotics were given in 986 infants (84%) for mean 9.6 days (range 1 -83). Neonatal intensive care complications were evident in 173 infants (14.8%), with at least one per infant. One hundred and thirty-six infants (79%) had one, 32 (18%) had two, and ve (3%) had three complications (total number of complications being 215). Infants with and without complications are depicted in (7), Enterococci (5), Enterobacter cloacae (2) and Staphylococcus aureus (2) . None was positive for LCR. Nine infants with LOS died, 3 of them directly following LOS. VAP was diagnosed in 31 infants (2.7%). Mean GA was 26 weeks (range 23.7 -28.7); BW was 773 grams (range 355 -1400). Male gender was predominant (61%) and 9 infants (19%) were SGA. Mean duration of mechanical ventilation was 67 days (range 20 -128). None of these infants died. A MODS was diagnosed in 32 infants (2.7%); mean GA was 28.6 weeks (23.3 -32.7), and BW was 1072 grams (370 -1970 Apgar score at 1 minute 6.9 ± 1.9 (8; 0-9)
Apgar score at 5 minutes 8.4 ± 1.3 (9; 0-10)
Apgar score at 10 minutes 8.9 ± 0.9 (9; 4-10)
Data are given as mean ± SD (median; range) or n (%) Apgar score at 1 minute 6 (0-9) 8 (0-9) <0.001
Apgar score at 5 minutes 8 (0-10) 9 (1-10) <0.001
Apgar score at 10 minutes 9 (4-10) 9 (4-10) <0.001 
DISCUSSION
Main ndings of our study address the safety aspect of probiotic therapy with LCR in the vulnerable population of very low birth weight infants. Over the 11 years lasting study period no side e ects were observed. In particular, no systemic LCR infection happened over the study period. Oral aminoglycosides have successfully been investigated in the prevention of NEC in some small past studies (20, 21) . Aminoglycosides have recently been reported to be e ective in preterm animal models of NEC prevention given in contrast to parenteral route (22) . Our use of enteral gentamycin is o en a matter of discussion. But there was neither an increase in detection rates of ESBL producing enterobacteria in stool surveillance cultures (done twice a week), nor an increase in gentamycin resistive bacteria as shown in the yearly published local hygiene report (data not shown). e third part of our triple anti-infective regimen is nystatin for prophylaxis of fungal infection. During study period, we observed no proven invasive fungal infection. A further aspect of our anti-infective regimen is based on the preferred feeding of human milk. Our data showed higher rates of human milk feeding in the group without complications Limitations of our study, which have to be mentioned, include the lower level of evidence of a retrospective cohort analysis and the missing control group. We decided against a control group (in order not to harm) due to the fact that a historical control might not be adequate and due to the belief in our concept. We aimed to publish the results of this large cohort of very low birth weight infants having received large amounts of LCR, gentamycin and nystatin. Strengths of our study include the low drop-out rate and the careful evaluation regarding prede ned complications.
Regarding the e cacy of this treatment regimen, in general we found low complication rates regarding NEC, LOS, VAP, and MODS, and no AAD. In our cohort analysis the NEC rate of 0.9 % was extremely low compared to studies included in the most recent Cochrane review (8) of median 2.3 % with probiotics and 5.4 % without (9, (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) ; the LOS rate of 12.1% (culture proven and clinical sepsis) was comparable to the median 14.8 % with probiotics and lower than the median 19.3 % without probiotics (23) (24) (25) (26) (27) (28) (32) (33) (34) (35) . e bene cial use of probiotics has also been systematically evaluated in preterm infants in low-and medium-income countries (43) . e review of randomized controlled trials revealed a signi cant reduction of NEC (number needed to treat -NNT = 25), LOS (NNT = 25) and all-cause mortality (NNT = 50); additionally, no signi cant adverse e ects were reported (43) . Another network meta-analysis investigated the e cacy and safety of probiotics, Data given as median (range) or n (%); GA = gestational age; LOS = late onset sepsis; MODS multi organ dysfunction syndrome; VAP = ventilator associated pneumonia; NEC = necrotizing enterocolitis Data are given as n (%) or median (range); SGA small for gestational age (< 10th percentile); LOS = late onset sepsis; MODS multi organ dysfunction syndrome; VAP = ventilator associated pneumonia; NEC = necrotizing enterocolitis GA = gestational age; NICU = neonatal intensive care unit; VP = very preterm; wks = weeks Figure 1 : Flow chart of study population recruitment (preterm infants 23 to 32 weeks of gestational age) from 2005 to 2015 at the NICU Graz, Austria probiotics plus fructo-oligosaccharides, pentoxifylline, arginine, and lactoferrin in NEC prevention (44) . Probiotics and Arginine performed better compared with placebo, but only probiotics achieved a considerable decrease of mortality rates. e main problem discussed in metaanalyses and systematic review is related to heterogeneity of organisms and dosing regimens studied (45); hence it is difcult to nd out the most e ective and safe single strain or the best combination of probiotics. Lactobacilli alone or in combination with Bi dobacteriae were found to be e ective in most of the reviews (46) All included trials reported no systemic infection with supplemental probiotics (47) us, our study adds to the favorable pro le of LCR reporting on 11 years of safe and well-tolerated use in very low birth weight infants. e question of safety has also been addressed by the European Society for Pediatric Gastroenterology (ES-PGAN) and the ESPGAN considered the use of probiotics in general safe (47) . Our data open the discussion of whether feeding all preterm infants with probiotics might be justi ed. It seems to be better justi ed to use one probiotic strain compared to multiples due to a better control for adverse events and e cacy, as shown by our data. We found a further low rate of VAP (2.7%). VAP has recently been reported to occur in 13.2% of a cohort of 605 low birth weight infants with a mean gestational age of 27 weeks (48); and an even two-fold increased rate of 28.3% has been observed in a cohort of 67 extremely preterm infants <28 weeks of gestational age (2) . Risk factor for VAP was a preceding bloodstream infection and VAP was per se an independent predictor of mortality (2) . As far as VAP is a factor associated with prolonged NICU length of stay, the reduction of VAP by probiotics as shown by our data seems to be highly coste ective at a rst glance. Multi-organ dysfunction is o en described as a common terminal pathway in the pathophysiology of sepsis and may include respiratory, cardiovascular, central nervous system, adrenal, clotting, immune (leukopenia or neutropenia), and renal dysfunction (49) . However, the timing of onset and frequency of these phenomena among hospitalized preterm infants with fatal disease are mainly unknown. e majority of fatal episodes have been reported to occur in extremely low birth weight infants during the rst four weeks of life. Hence, our rate of MODS is hardly comparable due to the lack of reported rates. Overall, our mortality rate was low with 2.48 % compared to the literature with median 4.4 % with, and 8.0 % without probiotics (9, (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (37) (38) (39) 50) . In conclusion, the use of LCR over 11 years in very low birth weight infants proved to be safe and complication rates including NEC, LOS, VAP and MODS were low compared to the literature
"WHAT IS ALREADY KNOWN"
Probiotics are known to lower the risk for necrotizing enterocolitis (NEC) and sepsis (LOS) and all-cause mortality by metaanalysis. Lactobacilli and Bi dobacteriae might be most e ective alone or in combination.
"WHAT THIS STUDY ADDS"
Lactobacillus casei rhamnosus (LCR) as part of a triple anti-infective regimen is effective in prevention of NEC and LOS and ventilator associated pneumonia. LCR proved to be safe without any case of invasive infection as demonstrated by its use over 11 years in more than 1.100 VLBW infants. 
